#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Schizophrenia is a severe mental illness that affects about one percent of the world ’s population .
2-1	16-29	Schizophrenia	abstract	new	coref	2-3[3_0]
2-2	30-32	is	_	_	_	_
2-3	33-34	a	abstract[3]	giv[3]	coref	3-4[0_3]
2-4	35-41	severe	abstract[3]	giv[3]	_	_
2-5	42-48	mental	abstract[3]	giv[3]	_	_
2-6	49-56	illness	abstract[3]	giv[3]	_	_
2-7	57-61	that	_	_	_	_
2-8	62-69	affects	_	_	_	_
2-9	70-75	about	person[4]	new[4]	_	_
2-10	76-79	one	person[4]	new[4]	_	_
2-11	80-87	percent	person[4]	new[4]	_	_
2-12	88-90	of	person[4]	new[4]	_	_
2-13	91-94	the	person[4]|abstract[6]	new[4]|new[6]	_	_
2-14	95-100	world	person[4]|place[5]|abstract[6]	new[4]|new[5]|new[6]	_	_
2-15	101-103	’s	person[4]|place[5]|abstract[6]	new[4]|new[5]|new[6]	_	_
2-16	104-114	population	person[4]|abstract[6]	new[4]|new[6]	_	_
2-17	115-116	.	_	_	_	_

#Text=The patients with schizophrenia are characterized with cognitive impairment , confusion , hallucinations and deterioration of social function .
3-1	117-120	The	person[7]	new[7]	coref	4-12[17_7]
3-2	121-129	patients	person[7]	new[7]	_	_
3-3	130-134	with	person[7]	new[7]	_	_
3-4	135-148	schizophrenia	person[7]|abstract	new[7]|giv	coref	4-5
3-5	149-152	are	_	_	_	_
3-6	153-166	characterized	_	_	_	_
3-7	167-171	with	_	_	_	_
3-8	172-181	cognitive	abstract[9]	new[9]	_	_
3-9	182-192	impairment	abstract[9]	new[9]	_	_
3-10	193-194	,	_	_	_	_
3-11	195-204	confusion	abstract	new	_	_
3-12	205-206	,	_	_	_	_
3-13	207-221	hallucinations	abstract	new	_	_
3-14	222-225	and	_	_	_	_
3-15	226-239	deterioration	abstract[12]	new[12]	_	_
3-16	240-242	of	abstract[12]	new[12]	_	_
3-17	243-249	social	abstract[12]|abstract[13]	new[12]|new[13]	ana	4-1[0_13]
3-18	250-258	function	abstract[12]|abstract[13]	new[12]|new[13]	_	_
3-19	259-260	.	_	_	_	_

#Text=It is noted that schizophrenia leads to a heavy burden on the patients , their families and society .
4-1	261-263	It	abstract	giv	_	_
4-2	264-266	is	_	_	_	_
4-3	267-272	noted	_	_	_	_
4-4	273-277	that	_	_	_	_
4-5	278-291	schizophrenia	abstract	giv	coref	5-11
4-6	292-297	leads	_	_	_	_
4-7	298-300	to	_	_	_	_
4-8	301-302	a	abstract[16]	new[16]	_	_
4-9	303-308	heavy	abstract[16]	new[16]	_	_
4-10	309-315	burden	abstract[16]	new[16]	_	_
4-11	316-318	on	abstract[16]	new[16]	_	_
4-12	319-322	the	abstract[16]|person[17]	new[16]|giv[17]	coref	16-38[119_17]
4-13	323-331	patients	abstract[16]|person[17]	new[16]|giv[17]	_	_
4-14	332-333	,	abstract[16]|person[17]	new[16]|giv[17]	_	_
4-15	334-339	their	abstract[16]|person[17]|person[18]	new[16]|giv[17]|new[18]	_	_
4-16	340-348	families	abstract[16]|person[17]|person[18]	new[16]|giv[17]|new[18]	_	_
4-17	349-352	and	abstract[16]|person[17]	new[16]|giv[17]	_	_
4-18	353-360	society	abstract[16]|person[17]|abstract	new[16]|giv[17]|new	_	_
4-19	361-362	.	_	_	_	_

#Text=Substantial efforts have been devoted to elucidating the pathophysiology of schizophrenia development from genetic and environmental perspectives , as well as gene-environment interactions .
5-1	363-374	Substantial	abstract[20]	new[20]	_	_
5-2	375-382	efforts	abstract[20]	new[20]	_	_
5-3	383-387	have	_	_	_	_
5-4	388-392	been	_	_	_	_
5-5	393-400	devoted	_	_	_	_
5-6	401-403	to	_	_	_	_
5-7	404-415	elucidating	_	_	_	_
5-8	416-419	the	abstract[21]	new[21]	_	_
5-9	420-435	pathophysiology	abstract[21]	new[21]	_	_
5-10	436-438	of	abstract[21]	new[21]	_	_
5-11	439-452	schizophrenia	abstract[21]|abstract|abstract[23]	new[21]|giv|new[23]	coref	6-13
5-12	453-464	development	abstract[21]|abstract[23]	new[21]|new[23]	_	_
5-13	465-469	from	abstract[21]|abstract[23]	new[21]|new[23]	_	_
5-14	470-477	genetic	abstract[21]|abstract[23]|abstract[24]	new[21]|new[23]|new[24]	_	_
5-15	478-481	and	abstract[21]|abstract[23]|abstract[24]	new[21]|new[23]|new[24]	_	_
5-16	482-495	environmental	abstract[21]|abstract[23]|abstract[24]	new[21]|new[23]|new[24]	_	_
5-17	496-508	perspectives	abstract[21]|abstract[23]|abstract[24]	new[21]|new[23]|new[24]	_	_
5-18	509-510	,	_	_	_	_
5-19	511-513	as	_	_	_	_
5-20	514-518	well	_	_	_	_
5-21	519-521	as	_	_	_	_
5-22	522-538	gene-environment	abstract|abstract[26]	new|new[26]	_	_
5-23	539-551	interactions	abstract[26]	new[26]	_	_
5-24	552-553	.	_	_	_	_

#Text=Epidemiological studies have suggested that urban environments could increase the risk of schizophrenia , which may be due to the exposure to the toxic heavy metals ( THMs ) in the environment .
6-1	554-569	Epidemiological	abstract[27]	new[27]	coref	15-2[105_27]
6-2	570-577	studies	abstract[27]	new[27]	_	_
6-3	578-582	have	_	_	_	_
6-4	583-592	suggested	_	_	_	_
6-5	593-597	that	_	_	_	_
6-6	598-603	urban	place[28]	new[28]	_	_
6-7	604-616	environments	place[28]	new[28]	_	_
6-8	617-622	could	_	_	_	_
6-9	623-631	increase	_	_	_	_
6-10	632-635	the	abstract[29]	new[29]	coref	9-7[0_29]
6-11	636-640	risk	abstract[29]	new[29]	_	_
6-12	641-643	of	abstract[29]	new[29]	_	_
6-13	644-657	schizophrenia	abstract[29]|abstract	new[29]|giv	coref	11-20[81_0]
6-14	658-659	,	_	_	_	_
6-15	660-665	which	_	_	_	_
6-16	666-669	may	_	_	_	_
6-17	670-672	be	_	_	_	_
6-18	673-676	due	_	_	_	_
6-19	677-679	to	_	_	_	_
6-20	680-683	the	abstract[31]	new[31]	coref	7-1[35_31]
6-21	684-692	exposure	abstract[31]	new[31]	_	_
6-22	693-695	to	abstract[31]	new[31]	_	_
6-23	696-699	the	abstract[31]|substance[32]	new[31]|new[32]	appos	6-28[0_32]
6-24	700-705	toxic	abstract[31]|substance[32]	new[31]|new[32]	_	_
6-25	706-711	heavy	abstract[31]|substance[32]	new[31]|new[32]	_	_
6-26	712-718	metals	abstract[31]|substance[32]	new[31]|new[32]	_	_
6-27	719-720	(	_	_	_	_
6-28	721-725	THMs	substance	giv	coref	7-4
6-29	726-727	)	_	_	_	_
6-30	728-730	in	_	_	_	_
6-31	731-734	the	place[34]	new[34]	_	_
6-32	735-746	environment	place[34]	new[34]	_	_
6-33	747-748	.	_	_	_	_

#Text=Chronic exposure to THMs impairs numerous biological functions and results in a series of health problems , such as aberrant immunological responses and neuropathological conditions .
7-1	749-756	Chronic	abstract[35]	giv[35]	coref	12-7[87_35]
7-2	757-765	exposure	abstract[35]	giv[35]	_	_
7-3	766-768	to	abstract[35]	giv[35]	_	_
7-4	769-773	THMs	abstract[35]|substance	giv[35]|giv	coref	8-8
7-5	774-781	impairs	_	_	_	_
7-6	782-790	numerous	abstract[37]	new[37]	_	_
7-7	791-801	biological	abstract[37]	new[37]	_	_
7-8	802-811	functions	abstract[37]	new[37]	_	_
7-9	812-815	and	_	_	_	_
7-10	816-823	results	abstract[38]	new[38]	coref	15-13[109_38]
7-11	824-826	in	abstract[38]	new[38]	_	_
7-12	827-828	a	abstract[38]|abstract[39]	new[38]|new[39]	ana	8-3[0_39]
7-13	829-835	series	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-14	836-838	of	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-15	839-845	health	abstract[38]|abstract[39]|abstract|abstract[41]	new[38]|new[39]|new|new[41]	_	_
7-16	846-854	problems	abstract[38]|abstract[39]|abstract[41]	new[38]|new[39]|new[41]	_	_
7-17	855-856	,	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-18	857-861	such	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-19	862-864	as	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-20	865-873	aberrant	abstract[38]|abstract[39]|abstract[42]	new[38]|new[39]|new[42]	_	_
7-21	874-887	immunological	abstract[38]|abstract[39]|abstract[42]	new[38]|new[39]|new[42]	_	_
7-22	888-897	responses	abstract[38]|abstract[39]|abstract[42]	new[38]|new[39]|new[42]	_	_
7-23	898-901	and	abstract[38]|abstract[39]	new[38]|new[39]	_	_
7-24	902-919	neuropathological	abstract[38]|abstract[39]|abstract[43]	new[38]|new[39]|new[43]	_	_
7-25	920-930	conditions	abstract[38]|abstract[39]|abstract[43]	new[38]|new[39]|new[43]	_	_
7-26	931-932	.	_	_	_	_

#Text=Moreover , it has been reported that THMs could cause oxidative stress and subsequently DNA damage , lipid peroxidation and protein modification , which play a role in the pathogenesis of numerous diseases , including cancer , diabetes , neurological disorders and chronic inflammation .
8-1	933-941	Moreover	_	_	_	_
8-2	942-943	,	_	_	_	_
8-3	944-946	it	abstract	giv	_	_
8-4	947-950	has	_	_	_	_
8-5	951-955	been	_	_	_	_
8-6	956-964	reported	_	_	_	_
8-7	965-969	that	_	_	_	_
8-8	970-974	THMs	substance	giv	coref	9-1
8-9	975-980	could	_	_	_	_
8-10	981-986	cause	_	_	_	_
8-11	987-996	oxidative	abstract|abstract[47]	new|new[47]	_	_
8-12	997-1003	stress	abstract[47]	new[47]	_	_
8-13	1004-1007	and	_	_	_	_
8-14	1008-1020	subsequently	abstract[49]	new[49]	_	_
8-15	1021-1024	DNA	substance|abstract[49]	new|new[49]	_	_
8-16	1025-1031	damage	abstract[49]	new[49]	_	_
8-17	1032-1033	,	_	_	_	_
8-18	1034-1039	lipid	person|substance[51]	new|new[51]	_	_
8-19	1040-1052	peroxidation	substance[51]	new[51]	_	_
8-20	1053-1056	and	_	_	_	_
8-21	1057-1064	protein	substance|abstract[53]	new|new[53]	coref	10-20[72_0]
8-22	1065-1077	modification	abstract[53]	new[53]	_	_
8-23	1078-1079	,	_	_	_	_
8-24	1080-1085	which	_	_	_	_
8-25	1086-1090	play	_	_	_	_
8-26	1091-1092	a	abstract[54]	new[54]	coref	24-22[184_54]
8-27	1093-1097	role	abstract[54]	new[54]	_	_
8-28	1098-1100	in	abstract[54]	new[54]	_	_
8-29	1101-1104	the	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-30	1105-1117	pathogenesis	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-31	1118-1120	of	abstract[54]|abstract[55]	new[54]|new[55]	_	_
8-32	1121-1129	numerous	abstract[54]|abstract[55]|abstract[56]	new[54]|new[55]|new[56]	coref	9-10[63_56]
8-33	1130-1138	diseases	abstract[54]|abstract[55]|abstract[56]	new[54]|new[55]|new[56]	_	_
8-34	1139-1140	,	abstract[54]|abstract[55]|abstract[56]	new[54]|new[55]|new[56]	_	_
8-35	1141-1150	including	abstract[54]|abstract[55]|abstract[56]	new[54]|new[55]|new[56]	_	_
8-36	1151-1157	cancer	abstract[54]|abstract[55]|abstract[56]|event	new[54]|new[55]|new[56]|new	_	_
8-37	1158-1159	,	abstract[54]|abstract[55]|abstract[56]	new[54]|new[55]|new[56]	_	_
8-38	1160-1168	diabetes	abstract[54]|abstract[55]|abstract[56]|abstract	new[54]|new[55]|new[56]|new	_	_
8-39	1169-1170	,	abstract[54]|abstract[55]|abstract[56]	new[54]|new[55]|new[56]	_	_
8-40	1171-1183	neurological	abstract[54]|abstract[55]|abstract[56]|abstract[59]	new[54]|new[55]|new[56]|new[59]	_	_
8-41	1184-1193	disorders	abstract[54]|abstract[55]|abstract[56]|abstract[59]	new[54]|new[55]|new[56]|new[59]	_	_
8-42	1194-1197	and	abstract[54]|abstract[55]|abstract[56]	new[54]|new[55]|new[56]	_	_
8-43	1198-1205	chronic	abstract[54]|abstract[55]|abstract[56]|abstract[60]	new[54]|new[55]|new[56]|new[60]	_	_
8-44	1206-1218	inflammation	abstract[54]|abstract[55]|abstract[56]|abstract[60]	new[54]|new[55]|new[56]|new[60]	_	_
8-45	1219-1220	.	_	_	_	_

#Text=THMs are suggested as an important risk factor for mental diseases since they cause neurobehavioral alterations and disrupt dopamine receptors .
9-1	1221-1225	THMs	abstract	giv	coref	13-5
9-2	1226-1229	are	_	_	_	_
9-3	1230-1239	suggested	_	_	_	_
9-4	1240-1242	as	_	_	_	_
9-5	1243-1245	an	_	_	_	_
9-6	1246-1255	important	_	_	_	_
9-7	1256-1260	risk	abstract	giv	coref	14-15[103_0]
9-8	1261-1267	factor	_	_	_	_
9-9	1268-1271	for	_	_	_	_
9-10	1272-1278	mental	abstract[63]	giv[63]	ana	9-13[0_63]
9-11	1279-1287	diseases	abstract[63]	giv[63]	_	_
9-12	1288-1293	since	_	_	_	_
9-13	1294-1298	they	abstract	giv	coref	10-34[75_0]
9-14	1299-1304	cause	_	_	_	_
9-15	1305-1320	neurobehavioral	abstract[65]	new[65]	_	_
9-16	1321-1332	alterations	abstract[65]	new[65]	_	_
9-17	1333-1336	and	_	_	_	_
9-18	1337-1344	disrupt	_	_	_	_
9-19	1345-1353	dopamine	abstract|object[67]	new|new[67]	_	_
9-20	1354-1363	receptors	object[67]	new[67]	_	_
9-21	1364-1365	.	_	_	_	_

#Text=For example , arsenic ( As ) -induced neurotoxicity has been reported to cause compositional changes and hyperphosphorylation on the cytoskeletal protein , leading to the disintegration of the cytoskeletal framework and causing neurodegenerative diseases .
10-1	1366-1369	For	_	_	_	_
10-2	1370-1377	example	_	_	_	_
10-3	1378-1379	,	_	_	_	_
10-4	1380-1387	arsenic	substance	new	_	_
10-5	1388-1389	(	_	_	_	_
10-6	1390-1392	As	_	_	_	_
10-7	1393-1394	)	_	_	_	_
10-8	1395-1403	-induced	_	_	_	_
10-9	1404-1417	neurotoxicity	abstract	new	_	_
10-10	1418-1421	has	_	_	_	_
10-11	1422-1426	been	_	_	_	_
10-12	1427-1435	reported	_	_	_	_
10-13	1436-1438	to	_	_	_	_
10-14	1439-1444	cause	_	_	_	_
10-15	1445-1458	compositional	abstract[70]	new[70]	coref	14-1[99_70]
10-16	1459-1466	changes	abstract[70]	new[70]	_	_
10-17	1467-1470	and	_	_	_	_
10-18	1471-1491	hyperphosphorylation	abstract[71]	new[71]	_	_
10-19	1492-1494	on	abstract[71]	new[71]	_	_
10-20	1495-1498	the	abstract[71]|substance[72]	new[71]|giv[72]	_	_
10-21	1499-1511	cytoskeletal	abstract[71]|substance[72]	new[71]|giv[72]	_	_
10-22	1512-1519	protein	abstract[71]|substance[72]	new[71]|giv[72]	_	_
10-23	1520-1521	,	_	_	_	_
10-24	1522-1529	leading	_	_	_	_
10-25	1530-1532	to	_	_	_	_
10-26	1533-1536	the	abstract[73]	new[73]	_	_
10-27	1537-1551	disintegration	abstract[73]	new[73]	_	_
10-28	1552-1554	of	abstract[73]	new[73]	_	_
10-29	1555-1558	the	abstract[73]|object[74]	new[73]|new[74]	_	_
10-30	1559-1571	cytoskeletal	abstract[73]|object[74]	new[73]|new[74]	_	_
10-31	1572-1581	framework	abstract[73]|object[74]	new[73]|new[74]	_	_
10-32	1582-1585	and	_	_	_	_
10-33	1586-1593	causing	_	_	_	_
10-34	1594-1611	neurodegenerative	abstract[75]	giv[75]	coref	24-18[183_75]
10-35	1612-1620	diseases	abstract[75]	giv[75]	_	_
10-36	1621-1622	.	_	_	_	_

#Text=An animal study showed lead ( Pb ) as an environmental toxin , which contributed to the pathogenesis of schizophrenia in Disrupted-in-Schizophrenia 1 ( Disc1)-mutant mice .
11-1	1623-1625	An	abstract[77]	new[77]	coref	12-16[90_77]
11-2	1626-1632	animal	person|abstract[77]	new|new[77]	_	_
11-3	1633-1638	study	abstract[77]	new[77]	_	_
11-4	1639-1645	showed	_	_	_	_
11-5	1646-1650	lead	substance	new	appos	11-7
11-6	1651-1652	(	_	_	_	_
11-7	1653-1655	Pb	substance	giv	coref	16-17
11-8	1656-1657	)	_	_	_	_
11-9	1658-1660	as	_	_	_	_
11-10	1661-1663	an	_	_	_	_
11-11	1664-1677	environmental	_	_	_	_
11-12	1678-1683	toxin	_	_	_	_
11-13	1684-1685	,	_	_	_	_
11-14	1686-1691	which	_	_	_	_
11-15	1692-1703	contributed	_	_	_	_
11-16	1704-1706	to	_	_	_	_
11-17	1707-1710	the	abstract[80]	new[80]	_	_
11-18	1711-1723	pathogenesis	abstract[80]	new[80]	_	_
11-19	1724-1726	of	abstract[80]	new[80]	_	_
11-20	1727-1740	schizophrenia	abstract[80]|abstract[81]	new[80]|giv[81]	coref	12-14[89_81]
11-21	1741-1743	in	abstract[80]|abstract[81]	new[80]|giv[81]	_	_
11-22	1744-1770	Disrupted-in-Schizophrenia	abstract[80]|abstract[81]|abstract[82]	new[80]|giv[81]|new[82]	_	_
11-23	1771-1772	1	abstract[80]|abstract[81]|abstract[82]	new[80]|giv[81]|new[82]	_	_
11-24	1773-1774	(	_	_	_	_
11-25	1775-1788	Disc1)-mutant	animal|animal[84]	new|new[84]	ana	13-16[0_84]
11-26	1789-1793	mice	animal[84]	new[84]	_	_
11-27	1794-1795	.	_	_	_	_

#Text=Therefore , investigating the association of environmental THM exposure with the risk of schizophrenia via a reliable epidemiological study is worthwhile .
12-1	1796-1805	Therefore	_	_	_	_
12-2	1806-1807	,	_	_	_	_
12-3	1808-1821	investigating	_	_	_	_
12-4	1822-1825	the	abstract[85]	new[85]	coref	15-6[106_85]
12-5	1826-1837	association	abstract[85]	new[85]	_	_
12-6	1838-1840	of	abstract[85]	new[85]	_	_
12-7	1841-1854	environmental	abstract[85]|abstract[87]	new[85]|giv[87]	coref	13-21[0_87]
12-8	1855-1858	THM	abstract[85]|substance|abstract[87]	new[85]|new|giv[87]	coref	14-3
12-9	1859-1867	exposure	abstract[85]|abstract[87]	new[85]|giv[87]	_	_
12-10	1868-1872	with	_	_	_	_
12-11	1873-1876	the	abstract[88]	new[88]	_	_
12-12	1877-1881	risk	abstract[88]	new[88]	_	_
12-13	1882-1884	of	abstract[88]	new[88]	_	_
12-14	1885-1898	schizophrenia	abstract[88]|abstract[89]	new[88]|giv[89]	coref	14-18[0_89]
12-15	1899-1902	via	abstract[88]|abstract[89]	new[88]|giv[89]	_	_
12-16	1903-1904	a	abstract[88]|abstract[89]|abstract[90]	new[88]|giv[89]|giv[90]	coref	16-21[114_90]
12-17	1905-1913	reliable	abstract[88]|abstract[89]|abstract[90]	new[88]|giv[89]|giv[90]	_	_
12-18	1914-1929	epidemiological	abstract[88]|abstract[89]|abstract[90]	new[88]|giv[89]|giv[90]	_	_
12-19	1930-1935	study	abstract[88]|abstract[89]|abstract[90]	new[88]|giv[89]|giv[90]	_	_
12-20	1936-1938	is	_	_	_	_
12-21	1939-1949	worthwhile	_	_	_	_
12-22	1950-1951	.	_	_	_	_

#Text=The serum concentration of THMs has been suggested to act as an internal indicator of their intake levels , reflecting exposure to environmental THMs .
13-1	1952-1955	The	quantity[92]	new[92]	_	_
13-2	1956-1961	serum	abstract|quantity[92]	new|new[92]	coref	19-6
13-3	1962-1975	concentration	quantity[92]	new[92]	_	_
13-4	1976-1978	of	quantity[92]	new[92]	_	_
13-5	1979-1983	THMs	quantity[92]|substance	new[92]|giv	coref	13-23[98_0]
13-6	1984-1987	has	_	_	_	_
13-7	1988-1992	been	_	_	_	_
13-8	1993-2002	suggested	_	_	_	_
13-9	2003-2005	to	_	_	_	_
13-10	2006-2009	act	_	_	_	_
13-11	2010-2012	as	_	_	_	_
13-12	2013-2015	an	_	_	_	_
13-13	2016-2024	internal	_	_	_	_
13-14	2025-2034	indicator	_	_	_	_
13-15	2035-2037	of	_	_	_	_
13-16	2038-2043	their	animal|abstract[96]	giv|new[96]	_	_
13-17	2044-2050	intake	event|abstract[96]	new|new[96]	_	_
13-18	2051-2057	levels	abstract[96]	new[96]	_	_
13-19	2058-2059	,	_	_	_	_
13-20	2060-2070	reflecting	_	_	_	_
13-21	2071-2079	exposure	abstract	giv	_	_
13-22	2080-2082	to	_	_	_	_
13-23	2083-2096	environmental	substance[98]	giv[98]	coref	15-9[107_98]
13-24	2097-2101	THMs	substance[98]	giv[98]	_	_
13-25	2102-2103	.	_	_	_	_

#Text=Changes in THM concentrations have been observed in peripheral tissues to be correlated with the risk of schizophrenia .
14-1	2104-2111	Changes	abstract[99]	giv[99]	_	_
14-2	2112-2114	in	abstract[99]	giv[99]	_	_
14-3	2115-2118	THM	abstract[99]|substance|abstract[101]	giv[99]|giv|new[101]	coref	25-22[196_101]
14-4	2119-2133	concentrations	abstract[99]|abstract[101]	giv[99]|new[101]	_	_
14-5	2134-2138	have	_	_	_	_
14-6	2139-2143	been	_	_	_	_
14-7	2144-2152	observed	_	_	_	_
14-8	2153-2155	in	_	_	_	_
14-9	2156-2166	peripheral	object[102]	new[102]	_	_
14-10	2167-2174	tissues	object[102]	new[102]	_	_
14-11	2175-2177	to	_	_	_	_
14-12	2178-2180	be	_	_	_	_
14-13	2181-2191	correlated	_	_	_	_
14-14	2192-2196	with	_	_	_	_
14-15	2197-2200	the	abstract[103]	giv[103]	coref	23-9[0_103]
14-16	2201-2205	risk	abstract[103]	giv[103]	_	_
14-17	2206-2208	of	abstract[103]	giv[103]	_	_
14-18	2209-2222	schizophrenia	abstract[103]|abstract	giv[103]|giv	coref	15-11
14-19	2223-2224	.	_	_	_	_

#Text=Although multiple studies have investigated the association between THMs and schizophrenia , the results remain inconsistent .
15-1	2225-2233	Although	_	_	_	_
15-2	2234-2242	multiple	abstract[105]	giv[105]	coref	22-2[160_105]
15-3	2243-2250	studies	abstract[105]	giv[105]	_	_
15-4	2251-2255	have	_	_	_	_
15-5	2256-2268	investigated	_	_	_	_
15-6	2269-2272	the	abstract[106]	giv[106]	coref	16-14[111_106]
15-7	2273-2284	association	abstract[106]	giv[106]	_	_
15-8	2285-2292	between	abstract[106]	giv[106]	_	_
15-9	2293-2297	THMs	abstract[106]|substance[107]	giv[106]|giv[107]	coref	22-9[162_107]
15-10	2298-2301	and	abstract[106]|substance[107]	giv[106]|giv[107]	_	_
15-11	2302-2315	schizophrenia	abstract[106]|substance[107]|abstract	giv[106]|giv[107]|giv	coref	16-19
15-12	2316-2317	,	_	_	_	_
15-13	2318-2321	the	abstract[109]	giv[109]	_	_
15-14	2322-2329	results	abstract[109]	giv[109]	_	_
15-15	2330-2336	remain	_	_	_	_
15-16	2337-2349	inconsistent	_	_	_	_
15-17	2350-2351	.	_	_	_	_

#Text=For example , despite supporting evidence both in vitro and in vivo for the association between Pb and schizophrenia , a cross-sectional study among a Chinese population showed no significant difference in the concentration of Pb between patients with schizophrenia and healthy controls .
16-1	2352-2355	For	_	_	_	_
16-2	2356-2363	example	_	_	_	_
16-3	2364-2365	,	_	_	_	_
16-4	2366-2373	despite	_	_	_	_
16-5	2374-2384	supporting	_	_	_	_
16-6	2385-2393	evidence	abstract	new	_	_
16-7	2394-2398	both	_	_	_	_
16-8	2399-2401	in	_	_	_	_
16-9	2402-2407	vitro	_	_	_	_
16-10	2408-2411	and	_	_	_	_
16-11	2412-2414	in	_	_	_	_
16-12	2415-2419	vivo	_	_	_	_
16-13	2420-2423	for	_	_	_	_
16-14	2424-2427	the	abstract[111]	giv[111]	coref	17-18[127_111]
16-15	2428-2439	association	abstract[111]	giv[111]	_	_
16-16	2440-2447	between	abstract[111]	giv[111]	_	_
16-17	2448-2450	Pb	abstract[111]|substance	giv[111]|giv	coref	16-36
16-18	2451-2454	and	abstract[111]	giv[111]	_	_
16-19	2455-2468	schizophrenia	abstract[111]|abstract	giv[111]|giv	coref	16-40
16-20	2469-2470	,	_	_	_	_
16-21	2471-2472	a	abstract[114]	giv[114]	coref	17-3[122_114]
16-22	2473-2488	cross-sectional	abstract[114]	giv[114]	_	_
16-23	2489-2494	study	abstract[114]	giv[114]	_	_
16-24	2495-2500	among	abstract[114]	giv[114]	_	_
16-25	2501-2502	a	abstract[114]|person[115]	giv[114]|new[115]	coref	18-13[131_115]
16-26	2503-2510	Chinese	abstract[114]|person[115]	giv[114]|new[115]	_	_
16-27	2511-2521	population	abstract[114]|person[115]	giv[114]|new[115]	_	_
16-28	2522-2528	showed	_	_	_	_
16-29	2529-2531	no	abstract[116]	new[116]	_	_
16-30	2532-2543	significant	abstract[116]	new[116]	_	_
16-31	2544-2554	difference	abstract[116]	new[116]	_	_
16-32	2555-2557	in	abstract[116]	new[116]	_	_
16-33	2558-2561	the	abstract[116]|quantity[117]	new[116]|new[117]	coref	19-11[141_117]
16-34	2562-2575	concentration	abstract[116]|quantity[117]	new[116]|new[117]	_	_
16-35	2576-2578	of	abstract[116]|quantity[117]	new[116]|new[117]	_	_
16-36	2579-2581	Pb	abstract[116]|quantity[117]|substance	new[116]|new[117]|giv	coref	24-11
16-37	2582-2589	between	abstract[116]|quantity[117]	new[116]|new[117]	_	_
16-38	2590-2598	patients	abstract[116]|quantity[117]|person[119]	new[116]|new[117]|giv[119]	coref	18-19[132_119]
16-39	2599-2603	with	abstract[116]|quantity[117]|person[119]	new[116]|new[117]|giv[119]	_	_
16-40	2604-2617	schizophrenia	abstract[116]|quantity[117]|person[119]|abstract	new[116]|new[117]|giv[119]|giv	coref	19-16
16-41	2618-2621	and	abstract[116]|quantity[117]|person[119]	new[116]|new[117]|giv[119]	_	_
16-42	2622-2629	healthy	abstract[116]|quantity[117]|person[119]|person[121]	new[116]|new[117]|giv[119]|new[121]	coref	19-13[142_121]
16-43	2630-2638	controls	abstract[116]|quantity[117]|person[119]|person[121]	new[116]|new[117]|giv[119]|new[121]	_	_
16-44	2639-2640	.	_	_	_	_

#Text=However , another study applying a very similar study design towards the same sampling region resulted in a significant association .
17-1	2641-2648	However	_	_	_	_
17-2	2649-2650	,	_	_	_	_
17-3	2651-2658	another	abstract[122]	giv[122]	coref	17-9[0_122]
17-4	2659-2664	study	abstract[122]	giv[122]	_	_
17-5	2665-2673	applying	_	_	_	_
17-6	2674-2675	a	abstract[124]	new[124]	_	_
17-7	2676-2680	very	abstract[124]	new[124]	_	_
17-8	2681-2688	similar	abstract[124]	new[124]	_	_
17-9	2689-2694	study	abstract|abstract[124]	giv|new[124]	coref	18-30
17-10	2695-2701	design	abstract[124]	new[124]	_	_
17-11	2702-2709	towards	abstract[124]	new[124]	_	_
17-12	2710-2713	the	abstract[124]|place[126]	new[124]|new[126]	_	_
17-13	2714-2718	same	abstract[124]|place[126]	new[124]|new[126]	_	_
17-14	2719-2727	sampling	abstract[124]|person|place[126]	new[124]|new|new[126]	_	_
17-15	2728-2734	region	abstract[124]|place[126]	new[124]|new[126]	_	_
17-16	2735-2743	resulted	_	_	_	_
17-17	2744-2746	in	_	_	_	_
17-18	2747-2748	a	abstract[127]	giv[127]	coref	22-6[161_127]
17-19	2749-2760	significant	abstract[127]	giv[127]	_	_
17-20	2761-2772	association	abstract[127]	giv[127]	_	_
17-21	2773-2774	.	_	_	_	_

#Text=The reason for the divergence may be related to the choice of the population , such as whether the schizophrenic patients have received antipsychotics drug during the time of study .
18-1	2775-2778	The	abstract[128]	new[128]	_	_
18-2	2779-2785	reason	abstract[128]	new[128]	_	_
18-3	2786-2789	for	abstract[128]	new[128]	_	_
18-4	2790-2793	the	abstract[128]|abstract[129]	new[128]|new[129]	_	_
18-5	2794-2804	divergence	abstract[128]|abstract[129]	new[128]|new[129]	_	_
18-6	2805-2808	may	_	_	_	_
18-7	2809-2811	be	_	_	_	_
18-8	2812-2819	related	_	_	_	_
18-9	2820-2822	to	_	_	_	_
18-10	2823-2826	the	abstract[130]	new[130]	_	_
18-11	2827-2833	choice	abstract[130]	new[130]	_	_
18-12	2834-2836	of	abstract[130]	new[130]	_	_
18-13	2837-2840	the	abstract[130]|person[131]	new[130]|giv[131]	_	_
18-14	2841-2851	population	abstract[130]|person[131]	new[130]|giv[131]	_	_
18-15	2852-2853	,	_	_	_	_
18-16	2854-2858	such	_	_	_	_
18-17	2859-2861	as	_	_	_	_
18-18	2862-2869	whether	_	_	_	_
18-19	2870-2873	the	person[132]	giv[132]	coref	19-16[144_132]
18-20	2874-2887	schizophrenic	person[132]	giv[132]	_	_
18-21	2888-2896	patients	person[132]	giv[132]	_	_
18-22	2897-2901	have	_	_	_	_
18-23	2902-2910	received	_	_	_	_
18-24	2911-2925	antipsychotics	abstract|substance[134]	new|new[134]	_	_
18-25	2926-2930	drug	substance[134]	new[134]	_	_
18-26	2931-2937	during	_	_	_	_
18-27	2938-2941	the	time[135]	new[135]	_	_
18-28	2942-2946	time	time[135]	new[135]	_	_
18-29	2947-2949	of	time[135]	new[135]	_	_
18-30	2950-2955	study	time[135]|abstract	new[135]|giv	coref	19-1[137_0]
18-31	2956-2957	.	_	_	_	_

#Text=A previous study has compared serum cadmium ( Cd ) concentration between healthy controls and schizophrenia patients with or without treatment .
19-1	2958-2959	A	abstract[137]	giv[137]	coref	25-5[189_137]
19-2	2960-2968	previous	abstract[137]	giv[137]	_	_
19-3	2969-2974	study	abstract[137]	giv[137]	_	_
19-4	2975-2978	has	_	_	_	_
19-5	2979-2987	compared	_	_	_	_
19-6	2988-2993	serum	abstract|substance[139]	giv|new[139]	appos|coref	19-9[0_139]|20-2
19-7	2994-3001	cadmium	substance[139]	new[139]	_	_
19-8	3002-3003	(	_	_	_	_
19-9	3004-3006	Cd	substance	giv	coref	20-5[148_0]
19-10	3007-3008	)	_	_	_	_
19-11	3009-3022	concentration	quantity[141]	giv[141]	_	_
19-12	3023-3030	between	quantity[141]	giv[141]	_	_
19-13	3031-3038	healthy	quantity[141]|person[142]	giv[141]|giv[142]	coref	20-16[151_142]
19-14	3039-3047	controls	quantity[141]|person[142]	giv[141]|giv[142]	_	_
19-15	3048-3051	and	quantity[141]|person[142]	giv[141]|giv[142]	_	_
19-16	3052-3065	schizophrenia	quantity[141]|person[142]|abstract|person[144]	giv[141]|giv[142]|giv|giv[144]	coref|coref	20-7[0_144]|21-19
19-17	3066-3074	patients	quantity[141]|person[142]|person[144]	giv[141]|giv[142]|giv[144]	_	_
19-18	3075-3079	with	_	_	_	_
19-19	3080-3082	or	_	_	_	_
19-20	3083-3090	without	_	_	_	_
19-21	3091-3100	treatment	abstract	new	coref	20-9
19-22	3101-3102	.	_	_	_	_

#Text=The serum concentration of Cd in patients after treatment was significantly higher than that of the healthy controls but no significant change was observed from the pre-treatment patients .
20-1	3103-3106	The	quantity[147]	new[147]	_	_
20-2	3107-3112	serum	abstract|quantity[147]	giv|new[147]	coref	25-22
20-3	3113-3126	concentration	quantity[147]	new[147]	_	_
20-4	3127-3129	of	quantity[147]	new[147]	_	_
20-5	3130-3132	Cd	quantity[147]|substance[148]	new[147]|giv[148]	_	_
20-6	3133-3135	in	quantity[147]|substance[148]	new[147]|giv[148]	_	_
20-7	3136-3144	patients	quantity[147]|substance[148]|person	new[147]|giv[148]|giv	coref	20-26[153_0]
20-8	3145-3150	after	_	_	_	_
20-9	3151-3160	treatment	event	giv	_	_
20-10	3161-3164	was	_	_	_	_
20-11	3165-3178	significantly	_	_	_	_
20-12	3179-3185	higher	_	_	_	_
20-13	3186-3190	than	_	_	_	_
20-14	3191-3195	that	_	_	_	_
20-15	3196-3198	of	_	_	_	_
20-16	3199-3202	the	person[151]	giv[151]	coref	25-15[193_151]
20-17	3203-3210	healthy	person[151]	giv[151]	_	_
20-18	3211-3219	controls	person[151]	giv[151]	_	_
20-19	3220-3223	but	_	_	_	_
20-20	3224-3226	no	abstract[152]	new[152]	_	_
20-21	3227-3238	significant	abstract[152]	new[152]	_	_
20-22	3239-3245	change	abstract[152]	new[152]	_	_
20-23	3246-3249	was	_	_	_	_
20-24	3250-3258	observed	_	_	_	_
20-25	3259-3263	from	_	_	_	_
20-26	3264-3267	the	person[153]	giv[153]	coref	21-13[158_153]
20-27	3268-3281	pre-treatment	person[153]	giv[153]	_	_
20-28	3282-3290	patients	person[153]	giv[153]	_	_
20-29	3291-3292	.	_	_	_	_

#Text=The concentration of antimony and uranium were also found significantly different between pre-treatment patients and post-treatment patients of schizophrenia .
21-1	3293-3296	The	abstract[154]	new[154]	_	_
21-2	3297-3310	concentration	abstract[154]	new[154]	_	_
21-3	3311-3313	of	abstract[154]	new[154]	_	_
21-4	3314-3322	antimony	abstract[154]|substance	new[154]|new	_	_
21-5	3323-3326	and	abstract[154]	new[154]	_	_
21-6	3327-3334	uranium	abstract[154]|substance	new[154]|new	_	_
21-7	3335-3339	were	_	_	_	_
21-8	3340-3344	also	_	_	_	_
21-9	3345-3350	found	_	_	_	_
21-10	3351-3364	significantly	_	_	_	_
21-11	3365-3374	different	_	_	_	_
21-12	3375-3382	between	_	_	_	_
21-13	3383-3396	pre-treatment	event|person[158]	new|giv[158]	coref	23-26[177_158]
21-14	3397-3405	patients	person[158]	giv[158]	_	_
21-15	3406-3409	and	person[158]	giv[158]	_	_
21-16	3410-3424	post-treatment	person[158]	giv[158]	_	_
21-17	3425-3433	patients	person[158]	giv[158]	_	_
21-18	3434-3436	of	person[158]	giv[158]	_	_
21-19	3437-3450	schizophrenia	person[158]|abstract	giv[158]|giv	coref	22-11
21-20	3451-3452	.	_	_	_	_

#Text=Although several studies have investigated the association between THMs and schizophrenia , the potential mechanisms which could link THMs and schizophrenia have not been elucidated .
22-1	3453-3461	Although	_	_	_	_
22-2	3462-3469	several	abstract[160]	giv[160]	coref	23-1[167_160]
22-3	3470-3477	studies	abstract[160]	giv[160]	_	_
22-4	3478-3482	have	_	_	_	_
22-5	3483-3495	investigated	_	_	_	_
22-6	3496-3499	the	abstract[161]	giv[161]	coref	25-19[194_161]
22-7	3500-3511	association	abstract[161]	giv[161]	_	_
22-8	3512-3519	between	abstract[161]	giv[161]	_	_
22-9	3520-3524	THMs	abstract[161]|abstract[162]	giv[161]|giv[162]	coref	22-19[165_162]
22-10	3525-3528	and	abstract[161]|abstract[162]	giv[161]|giv[162]	_	_
22-11	3529-3542	schizophrenia	abstract[161]|abstract[162]|abstract	giv[161]|giv[162]|giv	coref	22-21
22-12	3543-3544	,	_	_	_	_
22-13	3545-3548	the	abstract[164]	new[164]	_	_
22-14	3549-3558	potential	abstract[164]	new[164]	_	_
22-15	3559-3569	mechanisms	abstract[164]	new[164]	_	_
22-16	3570-3575	which	_	_	_	_
22-17	3576-3581	could	_	_	_	_
22-18	3582-3586	link	_	_	_	_
22-19	3587-3591	THMs	abstract[165]	giv[165]	coref	24-6[0_165]
22-20	3592-3595	and	abstract[165]	giv[165]	_	_
22-21	3596-3609	schizophrenia	abstract[165]|abstract	giv[165]|giv	coref	23-12
22-22	3610-3614	have	_	_	_	_
22-23	3615-3618	not	_	_	_	_
22-24	3619-3623	been	_	_	_	_
22-25	3624-3634	elucidated	_	_	_	_
22-26	3635-3636	.	_	_	_	_

#Text=Recent studies have suggested metabolic syndrome as a risk factor of schizophrenia , attributed to poor dietary habits , unhealthy lifestyle and physical inactivity of the patients and side-effects of the second generation-antipsychotics .
23-1	3637-3643	Recent	abstract[167]	giv[167]	coref	25-47[202_167]
23-2	3644-3651	studies	abstract[167]	giv[167]	_	_
23-3	3652-3656	have	_	_	_	_
23-4	3657-3666	suggested	_	_	_	_
23-5	3667-3676	metabolic	person|abstract[169]	new|new[169]	coref	24-18
23-6	3677-3685	syndrome	abstract[169]	new[169]	_	_
23-7	3686-3688	as	abstract[169]	new[169]	_	_
23-8	3689-3690	a	abstract[169]	new[169]	_	_
23-9	3691-3695	risk	abstract[169]|abstract	new[169]|giv	coref	25-51[203_0]
23-10	3696-3702	factor	abstract[169]	new[169]	_	_
23-11	3703-3705	of	abstract[169]	new[169]	_	_
23-12	3706-3719	schizophrenia	abstract[169]|abstract	new[169]|giv	coref	24-31
23-13	3720-3721	,	_	_	_	_
23-14	3722-3732	attributed	_	_	_	_
23-15	3733-3735	to	_	_	_	_
23-16	3736-3740	poor	abstract[173]	new[173]	_	_
23-17	3741-3748	dietary	abstract|abstract[173]	new|new[173]	_	_
23-18	3749-3755	habits	abstract[173]	new[173]	_	_
23-19	3756-3757	,	_	_	_	_
23-20	3758-3767	unhealthy	abstract[174]	new[174]	_	_
23-21	3768-3777	lifestyle	abstract[174]	new[174]	_	_
23-22	3778-3781	and	_	_	_	_
23-23	3782-3790	physical	abstract[175]	new[175]	_	_
23-24	3791-3801	inactivity	abstract[175]	new[175]	_	_
23-25	3802-3804	of	abstract[175]	new[175]	_	_
23-26	3805-3808	the	abstract[175]|person[176]|person[177]	new[175]|new[176]|giv[177]	coref|coref	25-9[191_176]|25-9[192_177]
23-27	3809-3817	patients	abstract[175]|person[176]|person[177]	new[175]|new[176]|giv[177]	_	_
23-28	3818-3821	and	abstract[175]|person[177]	new[175]|giv[177]	_	_
23-29	3822-3834	side-effects	abstract[175]|person[177]|abstract[178]	new[175]|giv[177]|new[178]	_	_
23-30	3835-3837	of	abstract[175]|person[177]|abstract[178]	new[175]|giv[177]|new[178]	_	_
23-31	3838-3841	the	abstract[175]|person[177]|abstract[178]|substance[179]	new[175]|giv[177]|new[178]|new[179]	_	_
23-32	3842-3848	second	abstract[175]|person[177]|abstract[178]|substance[179]	new[175]|giv[177]|new[178]|new[179]	_	_
23-33	3849-3874	generation-antipsychotics	abstract[175]|person[177]|abstract[178]|substance[179]	new[175]|giv[177]|new[178]|new[179]	_	_
23-34	3875-3876	.	_	_	_	_

#Text=On the other hand , THMs such as As and Pb were found to be associated with metabolic diseases , suggesting a role of abnormal metabolisms in linking THMs and schizophrenia .
24-1	3877-3879	On	_	_	_	_
24-2	3880-3883	the	_	_	_	_
24-3	3884-3889	other	_	_	_	_
24-4	3890-3894	hand	_	_	_	_
24-5	3895-3896	,	_	_	_	_
24-6	3897-3901	THMs	abstract	giv	coref	24-29[186_0]
24-7	3902-3906	such	_	_	_	_
24-8	3907-3909	as	_	_	_	_
24-9	3910-3912	As	_	_	_	_
24-10	3913-3916	and	_	_	_	_
24-11	3917-3919	Pb	substance	giv	coref	25-36
24-12	3920-3924	were	_	_	_	_
24-13	3925-3930	found	_	_	_	_
24-14	3931-3933	to	_	_	_	_
24-15	3934-3936	be	_	_	_	_
24-16	3937-3947	associated	_	_	_	_
24-17	3948-3952	with	_	_	_	_
24-18	3953-3962	metabolic	object|abstract[183]	giv|giv[183]	coref	26-9
24-19	3963-3971	diseases	abstract[183]	giv[183]	_	_
24-20	3972-3973	,	_	_	_	_
24-21	3974-3984	suggesting	_	_	_	_
24-22	3985-3986	a	abstract[184]	giv[184]	_	_
24-23	3987-3991	role	abstract[184]	giv[184]	_	_
24-24	3992-3994	of	abstract[184]	giv[184]	_	_
24-25	3995-4003	abnormal	abstract[184]|abstract[185]	giv[184]|new[185]	coref	26-16[209_185]
24-26	4004-4015	metabolisms	abstract[184]|abstract[185]	giv[184]|new[185]	_	_
24-27	4016-4018	in	_	_	_	_
24-28	4019-4026	linking	_	_	_	_
24-29	4027-4031	THMs	abstract[186]	giv[186]	coref	25-25[197_186]
24-30	4032-4035	and	abstract[186]	giv[186]	_	_
24-31	4036-4049	schizophrenia	abstract[186]|abstract	giv[186]|giv	coref	25-12
24-32	4050-4051	.	_	_	_	_

#Text=Therefore , we performed a case-control study with first-episode and drug-naïve schizophrenia patients and healthy controls to identify the association between serum concentrations of the 4 THMs ( i. e. , Cr , Cd , Pb and As , selected as commonly surveyed heavy metals in schizophrenia studies ) and the risk of schizophrenia .
25-1	4052-4061	Therefore	_	_	_	_
25-2	4062-4063	,	_	_	_	_
25-3	4064-4066	we	person	acc	_	_
25-4	4067-4076	performed	_	_	_	_
25-5	4077-4078	a	abstract[189]	giv[189]	_	_
25-6	4079-4091	case-control	abstract[189]	giv[189]	_	_
25-7	4092-4097	study	abstract[189]	giv[189]	_	_
25-8	4098-4102	with	abstract[189]	giv[189]	_	_
25-9	4103-4116	first-episode	abstract[189]|person[191]|person[192]	giv[189]|giv[191]|giv[192]	_	_
25-10	4117-4120	and	abstract[189]|person[191]|person[192]	giv[189]|giv[191]|giv[192]	_	_
25-11	4121-4131	drug-naïve	abstract[189]|person[191]|person[192]	giv[189]|giv[191]|giv[192]	_	_
25-12	4132-4145	schizophrenia	abstract[189]|abstract|person[191]|person[192]	giv[189]|giv|giv[191]|giv[192]	coref	25-47
25-13	4146-4154	patients	abstract[189]|person[191]|person[192]	giv[189]|giv[191]|giv[192]	_	_
25-14	4155-4158	and	abstract[189]|person[192]	giv[189]|giv[192]	_	_
25-15	4159-4166	healthy	abstract[189]|person[192]|person[193]	giv[189]|giv[192]|giv[193]	_	_
25-16	4167-4175	controls	abstract[189]|person[192]|person[193]	giv[189]|giv[192]|giv[193]	_	_
25-17	4176-4178	to	_	_	_	_
25-18	4179-4187	identify	_	_	_	_
25-19	4188-4191	the	abstract[194]	giv[194]	coref	27-9[213_194]
25-20	4192-4203	association	abstract[194]	giv[194]	_	_
25-21	4204-4211	between	abstract[194]	giv[194]	_	_
25-22	4212-4217	serum	abstract[194]|substance|abstract[196]	giv[194]|giv|giv[196]	_	_
25-23	4218-4232	concentrations	abstract[194]|abstract[196]	giv[194]|giv[196]	_	_
25-24	4233-4235	of	abstract[194]|abstract[196]	giv[194]|giv[196]	_	_
25-25	4236-4239	the	abstract[194]|abstract[196]|abstract[197]	giv[194]|giv[196]|giv[197]	appos	25-29[198_197]
25-26	4240-4241	4	abstract[194]|abstract[196]|abstract[197]	giv[194]|giv[196]|giv[197]	_	_
25-27	4242-4246	THMs	abstract[194]|abstract[196]|abstract[197]	giv[194]|giv[196]|giv[197]	_	_
25-28	4247-4248	(	_	_	_	_
25-29	4249-4251	i.	abstract[198]	giv[198]	coref	25-44[200_198]
25-30	4252-4254	e.	abstract[198]	giv[198]	_	_
25-31	4255-4256	,	abstract[198]	giv[198]	_	_
25-32	4257-4259	Cr	abstract[198]	giv[198]	_	_
25-33	4260-4261	,	abstract[198]	giv[198]	_	_
25-34	4262-4264	Cd	abstract[198]	giv[198]	_	_
25-35	4265-4266	,	abstract[198]	giv[198]	_	_
25-36	4267-4269	Pb	abstract[198]|abstract	giv[198]|giv	_	_
25-37	4270-4273	and	_	_	_	_
25-38	4274-4276	As	_	_	_	_
25-39	4277-4278	,	_	_	_	_
25-40	4279-4287	selected	_	_	_	_
25-41	4288-4290	as	_	_	_	_
25-42	4291-4299	commonly	_	_	_	_
25-43	4300-4308	surveyed	_	_	_	_
25-44	4309-4314	heavy	substance[200]	giv[200]	coref	26-4[206_200]
25-45	4315-4321	metals	substance[200]	giv[200]	_	_
25-46	4322-4324	in	substance[200]	giv[200]	_	_
25-47	4325-4338	schizophrenia	substance[200]|abstract|abstract[202]	giv[200]|giv|giv[202]	coref	25-54
25-48	4339-4346	studies	substance[200]|abstract[202]	giv[200]|giv[202]	_	_
25-49	4347-4348	)	substance[200]	giv[200]	_	_
25-50	4349-4352	and	substance[200]	giv[200]	_	_
25-51	4353-4356	the	substance[200]|abstract[203]	giv[200]|giv[203]	coref	27-17[215_203]
25-52	4357-4361	risk	substance[200]|abstract[203]	giv[200]|giv[203]	_	_
25-53	4362-4364	of	substance[200]|abstract[203]	giv[200]|giv[203]	_	_
25-54	4365-4378	schizophrenia	substance[200]|abstract[203]|abstract	giv[200]|giv[203]|giv	coref	26-24
25-55	4379-4380	.	_	_	_	_

#Text=The correlations between the 4 THMs and multiple metabolic biomarkers were also tested to explore the potential metabolisms associated between these THMs and schizophrenia .
26-1	4381-4384	The	abstract[205]	new[205]	_	_
26-2	4385-4397	correlations	abstract[205]	new[205]	_	_
26-3	4398-4405	between	abstract[205]	new[205]	_	_
26-4	4406-4409	the	abstract[205]|abstract[206]	new[205]|giv[206]	coref	26-21[210_206]
26-5	4410-4411	4	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
26-6	4412-4416	THMs	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
26-7	4417-4420	and	abstract[205]|abstract[206]	new[205]|giv[206]	_	_
26-8	4421-4429	multiple	abstract[205]|abstract[206]|abstract[208]	new[205]|giv[206]|new[208]	_	_
26-9	4430-4439	metabolic	abstract[205]|abstract[206]|person|abstract[208]	new[205]|giv[206]|giv|new[208]	_	_
26-10	4440-4450	biomarkers	abstract[205]|abstract[206]|abstract[208]	new[205]|giv[206]|new[208]	_	_
26-11	4451-4455	were	_	_	_	_
26-12	4456-4460	also	_	_	_	_
26-13	4461-4467	tested	_	_	_	_
26-14	4468-4470	to	_	_	_	_
26-15	4471-4478	explore	_	_	_	_
26-16	4479-4482	the	abstract[209]	giv[209]	_	_
26-17	4483-4492	potential	abstract[209]	giv[209]	_	_
26-18	4493-4504	metabolisms	abstract[209]	giv[209]	_	_
26-19	4505-4515	associated	_	_	_	_
26-20	4516-4523	between	_	_	_	_
26-21	4524-4529	these	abstract[210]	giv[210]	coref	27-12[214_210]
26-22	4530-4534	THMs	abstract[210]	giv[210]	_	_
26-23	4535-4538	and	abstract[210]	giv[210]	_	_
26-24	4539-4552	schizophrenia	abstract[210]|abstract	giv[210]|giv	coref	27-20
26-25	4553-4554	.	_	_	_	_

#Text=Furthermore , meta-analysis was conducted to comprehensively summarize the association between the 4 individual THMs and the risk of schizophrenia .
27-1	4555-4566	Furthermore	_	_	_	_
27-2	4567-4568	,	_	_	_	_
27-3	4569-4582	meta-analysis	abstract	new	_	_
27-4	4583-4586	was	_	_	_	_
27-5	4587-4596	conducted	_	_	_	_
27-6	4597-4599	to	_	_	_	_
27-7	4600-4615	comprehensively	_	_	_	_
27-8	4616-4625	summarize	_	_	_	_
27-9	4626-4629	the	abstract[213]	giv[213]	_	_
27-10	4630-4641	association	abstract[213]	giv[213]	_	_
27-11	4642-4649	between	abstract[213]	giv[213]	_	_
27-12	4650-4653	the	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
27-13	4654-4655	4	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
27-14	4656-4666	individual	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
27-15	4667-4671	THMs	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
27-16	4672-4675	and	abstract[213]|abstract[214]	giv[213]|giv[214]	_	_
27-17	4676-4679	the	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
27-18	4680-4684	risk	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
27-19	4685-4687	of	abstract[213]|abstract[214]|abstract[215]	giv[213]|giv[214]|giv[215]	_	_
27-20	4688-4701	schizophrenia	abstract[213]|abstract[214]|abstract[215]|abstract	giv[213]|giv[214]|giv[215]|giv	_	_
27-21	4702-4703	.	_	_	_	_
